Alenka Brzulja
Vice President of Cardiovascular & Specialty Solutions EMEA, Johnson & Johnson Medical Devices Companies
Vice President of Cardiovascular & Specialty Solutions EMEA, Johnson & Johnson Medical Devices Companies. Alenka joined Johnson & Johnson more than 20 years ago and has held several roles of increasing local and regional responsibility across Johnson & Johnson sectors. A MedTech enthusiast who continues to challenge what’s possible in healthcare, towards ensuring that each patient can access the technology and solutions that can make a meaningful difference to their health, every day.
In her current role, Alenka leads Biosense Webster, Cerenovus and Mentor companies which develop innovative technologies in the field of cardiac arrhythmias treatment, ischemic and hemorrhagic stroke treatment and breast surgery.
Alenka holds an Economics degree from the University of Ljubljana and obtained her MBA from Hofstra University in New York. She resides in Slovenia with her family.
3 blogs from the author
Posted on 13.10.2021
How innovation is transforming stroke care?
Many of us know someone affected by stroke. It is the second leading cause of death globally and results in 50% of survivors being chronically disabled.[1] In Europe, the incident of stroke will have increased by 34% by the middle of the next decade. [2] The impact of stroke The impact on individuals and families […]
Posted on 05.06.2020
How a focus on efficiency can help treat more atrial fibrillation patients
This blog is part of a blog series that showcases the medtech role in the different phases of the COVID-19 pandemic. Read here more COVID-19 related blogs. More info on MedTech Europe’s info hub. Before COVID-19 hit, there were around 11 million people across Europe living with atrial fibrillation (AF). As many as one in four […]
Posted on 05.12.2019
Millions of patients suffering with AF may be missing out on a life-saving procedure
Our recently published report examining the available treatment options for Atrial Fibrillation (AF) across Europe has found that millions of patients suffering with the condition don’t have access to a potentially life-saving treatment — catheter ablation therapy. Currently, 11 million people in Europe are affected by AF, a condition characterized by an irregular and often […]
Medtech Views
Curated by
